Yellow fever
disease diseaseOn this page
Also known as bronze Johnsylvatic yellow feverYellow fever virus caused disease or disorderYellow fever virus disease or disorderYellow fever Virus infectionYellow fever virus infectious diseaseYellow JackYF
Summary
Yellow fever (MONDO:0020502) is a disease and 40 clinical trials. Top therapeutic interventions include cholecalciferol, japanese encephalitis virus, inactivated, and metformin. A subtype of Flaviviridae infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 47
- Clinical trials: 40
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | <1 / 1 000 000 | Europe | Validated |
Signs & symptoms
Clinical features (HPO)
47 HPO clinical features (Orphanet curated; top 47 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001945 | Fever | Very frequent (80-99%) |
| HP:0002018 | Nausea | Very frequent (80-99%) |
| HP:0003496 | Increased circulating IgM level | Very frequent (80-99%) |
| HP:0020071 | Viremia | Very frequent (80-99%) |
| HP:0031964 | Elevated circulating alanine aminotransferase concentration | Very frequent (80-99%) |
| HP:0000083 | Renal insufficiency | Frequent (30-79%) |
| HP:0001662 | Bradycardia | Frequent (30-79%) |
| HP:0001892 | Abnormal bleeding | Frequent (30-79%) |
| HP:0001919 | Acute kidney injury | Frequent (30-79%) |
| HP:0001942 | Metabolic acidosis | Frequent (30-79%) |
| HP:0002013 | Vomiting | Frequent (30-79%) |
| HP:0002027 | Abdominal pain | Frequent (30-79%) |
| HP:0002248 | Hematemesis | Frequent (30-79%) |
| HP:0002315 | Headache | Frequent (30-79%) |
| HP:0002829 | Arthralgia | Frequent (30-79%) |
| HP:0003236 | Elevated circulating creatine kinase concentration | Frequent (30-79%) |
| HP:0003259 | Elevated circulating creatinine concentration | Frequent (30-79%) |
| HP:0003326 | Myalgia | Frequent (30-79%) |
| HP:0006277 | Pancreatic hyperplasia | Frequent (30-79%) |
| HP:0025143 | Chills | Frequent (30-79%) |
| HP:0030139 | Excessive bleeding after a venipuncture | Frequent (30-79%) |
| HP:0030783 | Increased circulating interleukin 6 concentration | Frequent (30-79%) |
| HP:0031956 | Elevated circulating aspartate aminotransferase concentration | Frequent (30-79%) |
| HP:0000952 | Jaundice | Occasional (5-29%) |
| HP:0001250 | Seizure | Occasional (5-29%) |
| HP:0001259 | Coma | Occasional (5-29%) |
| HP:0001735 | Acute pancreatitis | Occasional (5-29%) |
| HP:0001873 | Thrombocytopenia | Occasional (5-29%) |
| HP:0001974 | Leukocytosis | Occasional (5-29%) |
| HP:0002014 | Diarrhea | Occasional (5-29%) |
| HP:0002904 | Hyperbilirubinemia | Occasional (5-29%) |
| HP:0003225 | Reduced coagulation factor V activity | Occasional (5-29%) |
| HP:0003419 | Low back pain | Occasional (5-29%) |
| HP:0005115 | Supraventricular arrhythmia | Occasional (5-29%) |
| HP:0008151 | Prolonged prothrombin time | Occasional (5-29%) |
| HP:0011897 | Neutrophilia | Occasional (5-29%) |
| HP:0011900 | Hypofibrinogenemia | Occasional (5-29%) |
| HP:0030005 | Capillary leak | Occasional (5-29%) |
| HP:0031273 | Shock | Occasional (5-29%) |
| HP:0032066 | Decreased serum bicarbonate concentration | Occasional (5-29%) |
| HP:0000988 | Skin rash | Very rare (<1-4%) |
| HP:0002133 | Status epilepticus | Very rare (<1-4%) |
| HP:0002516 | Increased intracranial pressure | Very rare (<1-4%) |
| HP:0011029 | Internal hemorrhage | Very rare (<1-4%) |
| HP:0012664 | Reduced left ventricular ejection fraction | Very rare (<1-4%) |
| HP:0031690 | Opportunistic infection | Very rare (<1-4%) |
| HP:0100519 | Anuria | Very rare (<1-4%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | yellow fever |
| Mondo ID | MONDO:0020502 |
| MeSH | D015004 |
| Orphanet | 99829 |
| DOID | DOID:9682 |
| ICD-10-CM | A95 |
| ICD-11 | 383352795 |
| NCIT | C35547 |
| UMLS | C0043395 |
| MedGen | 53112 |
| GARD | 0007914 |
| MedDRA | 10048240 |
| NORD | 1873 |
| Is cancer (heuristic) | no |
Also known as: bronze John · sylvatic yellow fever · Yellow fever virus caused disease or disorder · Yellow fever virus disease or disorder · Yellow fever Virus infection · Yellow fever virus infectious disease · Yellow Jack · YF
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Flaviviridae infectious disease › yellow fever
Related subtypes (9): Powassan encephalitis, Murray valley encephalitis, West Nile fever, dengue disease, pestivirus infectious disease, st. Louis encephalitis, Kyasanur forest disease, Omsk hemorrhagic fever, Zika virus infectious disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 40.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 11 |
| PHASE3 | 8 |
| PHASE2 | 8 |
| PHASE1 | 6 |
| PHASE4 | 5 |
| PHASE1/PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00694655 | PHASE4 | COMPLETED | Human Immune Responses to Yellow Fever Vaccination |
| NCT01290055 | PHASE4 | COMPLETED | Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine |
| NCT02991495 | PHASE4 | COMPLETED | Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) |
| NCT03725618 | PHASE4 | COMPLETED | Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old |
| NCT04059471 | PHASE4 | COMPLETED | Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine |
| NCT06815835 | PHASE3 | NOT_YET_RECRUITING | Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months |
| NCT01426243 | PHASE3 | COMPLETED | The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. |
| NCT01436396 | PHASE3 | COMPLETED | Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers |
| NCT01466387 | PHASE3 | COMPLETED | A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults |
| NCT05332197 | PHASE3 | UNKNOWN | Booster Vaccine for Yellow Fever |
| NCT05421611 | PHASE3 | COMPLETED | A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL |
| NCT05447377 | PHASE3 | UNKNOWN | A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants |
| NCT07222059 | PHASE3 | COMPLETED | Phase 3 Single Arm, Open Study on vYF in Adults |
| NCT04942210 | PHASE2 | ACTIVE_NOT_RECRUITING | Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA |
| NCT05011123 | PHASE2 | ACTIVE_NOT_RECRUITING | Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia |
| NCT05859490 | PHASE1/PHASE2 | RECRUITING | Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination |
| NCT00982137 | PHASE2 | COMPLETED | Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) |
| NCT01488890 | PHASE2 | COMPLETED | Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine |
| NCT01943305 | PHASE2 | COMPLETED | The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans |
| NCT03116802 | PHASE2 | COMPLETED | Yellow Fever Vaccine on Statin/ Non Statin Subjects |
| NCT04267809 | PHASE2 | COMPLETED | Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection |
| NCT04269265 | PHASE1/PHASE2 | COMPLETED | The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination |
| NCT05568953 | PHASE2 | UNKNOWN | An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity |
| NCT00995865 | PHASE1 | COMPLETED | Trial of Yellow Fever Inactivated Vaccine |
| NCT02743455 | PHASE1 | COMPLETED | A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers |
| NCT03891420 | PHASE1 | TERMINATED | A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 |
| NCT04142086 | PHASE1 | COMPLETED | Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults |
| NCT05172544 | PHASE1 | COMPLETED | Trial of an Inactivated Yellow Fever Virus Vaccine |
| NCT06998004 | PHASE1 | COMPLETED | A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults |
| NCT05450770 | Not specified | NOT_YET_RECRUITING | Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination |
| NCT05644145 | Not specified | ACTIVE_NOT_RECRUITING | Immunogenicity of Yellow Fever Vaccine in a Pediatric Population Vaccinated at 12-23 Months of Age in Argentina |
| NCT07358910 | Not specified | RECRUITING | Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective |
| NCT00616356 | Not specified | COMPLETED | Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults |
| NCT02572518 | Not specified | COMPLETED | Immunity After Two Doses of Yellow Fever Vaccine |
| NCT02990182 | Not specified | UNKNOWN | Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children |
| NCT03541694 | Not specified | COMPLETED | Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea |
| NCT03870061 | Not specified | COMPLETED | Evaluation of an Infant Immunization Encouragement Program in Nigeria |
| NCT04235361 | Not specified | UNKNOWN | Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC |
| NCT05901454 | Not specified | UNKNOWN | Yellow Fever Human Infection Model With YF-17D |
| NCT06539351 | Not specified | COMPLETED | A Pilot Study to Finetune Skin Processing Procedures in Recent Vaccinees, Prior to GeKoSkimm Study Initiation (GeKoSkimm-pilot) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CHOLECALCIFEROL | 4 | 1 |
| JAPANESE ENCEPHALITIS VIRUS, INACTIVATED | 4 | 1 |
| METFORMIN | 4 | 1 |
| YELLOW FEVER VACCINE | 3 | 14 |
| RABIES VACCINE | 3 | 1 |
| SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN | 3 | 1 |
| TYPHOID VI POLYSACCHARIDE VACCINE | 3 | 1 |
| GALIDESIVIR | 2 | 1 |
| CHEMBL5287375 | 0 | 1 |